Canaccord raised the firm’s price target on Edwards Lifesciences (EW) to $71 from $66 and keeps a Hold rating on the shares. The firm said they delivered a solid Q4 and management reiterated guidance issued in December at the company’s investor day and provided Q1/25 guidance that, most notably, included total company and TAVR year-over-year growth rates below the low end of the FY25 expectations due to one less selling day in Q1/25.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences: Strong Q4 Performance Overshadowed by Unchanged 2025 Outlook and Capacity Constraints
- Edwards Lifesciences’ Earnings Call Highlights Strong Growth
- Early notable gainers among liquid option names on February 12th
- Edwards Lifesciences price target raised to $90 from $88 at Barclays
- Edwards Lifesciences price target raised to $75 from $70 at Morgan Stanley